US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Moderna, Inc. - Common Stock (NQ:MRNA)

221.72 -1.04 (-0.47%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stay informed with the top movers within the S&P500 index on Wednesday. ↗
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Moderna to Host Investor Event - Science Day
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Why Is Moderna (MRNA) Stock Soaring Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.1% in the afternoon session after investors positioned ahead of a pivotal FDA a... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
From Moderna, Inc.
Via ACCESS Newswire
News headline image
A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Stocks Under $50 That Fall Short
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
News headline image
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? ↗
It's important to consider your comfort with risk before diving in. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
3 Unpopular Stocks We Steer Clear Of
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Does Moderna Need to Start Making Money? ↗
Moderna Is Losing Billions. Here's Why That Might Be Exactly the Right Strategy. 
Via The Motley Fool
News headline image
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
Via ACCESS Newswire
News headline image
3 ETFs For the Coming Genomics Revolution ↗
Genomics companies are an exciting frontier in health care, and ETFs can help to diversify to control risk while positioning investors to benefit. 
Via MarketBeat
Topics ETFs
News headline image
Why Is Moderna (MRNA) Stock Rocketing Higher Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's positive momentum was extended as... 
Via StockStory
Wednesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
From BioMedWire
Via GlobeNewswire
News headline image
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 ↗
It is finally bouncing back after several challenging years. 
Via The Motley Fool
News headline image
Moderna to Present at Upcoming Conference in June 2026
Via ACCESS Newswire
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
News headline image
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
Via ACCESS Newswire
News headline image
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
Via ACCESS Newswire
News headline image
Anterix Stock Is Up 140%. Here's Why One Investor Just Bought $15.8 Million ↗
Anterix enables secure wireless communications for utilities and critical infrastructure through its nationwide 900 MHz spectrum portfolio. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Cash-Burning Stocks with Open Questions
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy
News headline image
2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in t... 
Via StockStory
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >